Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel
NASDAQ:SNGX

Soligenix Q3 2026 Earnings Date & Estimates

Soligenix logo
$0.34 +0.01 (+2.15%)
As of 03:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Soligenix is estimated to report Q3 2026 earnings on Friday, November 6, 2026. The conference call is scheduled for 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Soligenix in Q3 2026

Soligenix is expected to post earnings of -$0.12 per share. In the same quarter a year earlier Soligenix reported -$0.58 per share. Soligenix last reported on August 7, 2026, posting -$0.12 per share and beating the -$0.1550 consensus estimate. Soligenix has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.12
Prior-Year EPS
-$0.58

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.12 (Beat by +$0.0350)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Soligenix Q3 2026 Earnings FAQ

Soligenix (NASDAQ:SNGX) is estimated to report Q3 2026 earnings on Friday, November 6, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Soligenix's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Soligenix to post earnings of -$0.12 per share for Q3 2026.

Soligenix Earnings Headlines

Head to Head Comparison: Cartesian Therapeutics (NASDAQ:RNAC) versus Soligenix (NASDAQ:SNGX)
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084321
SNGX: Applying for Vaccine Development Funding for Ebola Vaccine
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sngx-applying-vaccine-development-funding-112500628.html
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
October 14 at 1:00 AM  |  The Oxford Club (Ad)
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
August 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-announces-recent-updates-and-second-quarter-2026-financial-results-302845724.html
Soligenix Expands At-the-Market Equity Offering Capacity
June 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/soligenix-expands-at-the-market-equity-offering-capacity?utm_source=marketbeat.com&utm_medium=referral
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
June 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/soligenix-applying-for-vaccine-development-funding-for-bundibugyo-ebola-vaccine-302793388.html
See More Soligenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Soligenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soligenix and other key companies, straight to your email.

About Soligenix

Soligenix (NASDAQ:SNGX), Inc. is a biopharmaceutical company focused on developing treatments for rare diseases and medical conditions with limited therapeutic options. The company’s programs target dermatologic, gastrointestinal, inflammatory and infectious diseases, with an emphasis on products that may address significant unmet medical needs.

Soligenix’s development portfolio has included HyBryte (synthetic hypericin), a photodynamic therapy candidate for cutaneous T-cell lymphoma, as well as dusquet, an innate defense regulator peptide being evaluated for inflammatory conditions such as oral mucositis and Behçet’s disease. The company has also developed specialized platforms designed to improve the stability of vaccines and other biologic products, including its ThermoVax technology.

Historically, Soligenix has pursued both biotherapeutic and biodefense programs, including candidates for gastrointestinal graft-versus-host disease and medical countermeasures for potential public-health threats. The company is headquartered in Princeton, New Jersey, and is led by President and Chief Executive Officer Christopher J. Schaber.

View Soligenix Profile
Earnings Tools